Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Frank Buck who wrote (1334)	1/31/1998 1:31:00 AM
From: Cisco	Read Replies (1) \| Respond to of 1894

Frank, I would but Morphometrix and AccuMed in one group. NeoPath and Neuromedical is clearly aiming at primary screening and should be in a separate group! ChromVision is used currently for screening blood for certain malignancies. Probably closer to AccuMed and Morphometrix in its technology than NeoPath and Neuromedical. You also left out Matritech and its Nuclear matrix Protein Technology! I believe it is in a group by itself. I would also put Speculite in a group by itself. I believe Digene's DNA Assay sounds a lot like AcCell-Savant! Cytology West?? Beats Me, I don't know this one! Cisco